EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Changes in gut microbiota and lactose intolerance symptoms before and after daily lactose supplementation in individuals with the lactase nonpersistent genotype

Lonneke JanssenDuijghuijsen, Ellen Looijesteijn, Maartje van den Belt, Beatrix Gerhard, Martin Ziegler, Renata Ariens, Reina Tjoelker, Jan Geurts

The American Journal of Clinical Nutrition · 2024-03 · 119 (3) · 702-710

DOI: 10.1016/j.ajcnut.2023.12.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal of Clinical Nutrition, 2024-03. Verfasst von Lonneke JanssenDuijghuijsen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Wageningen Food and Biobased Research, Wageningen University & Research, Wageningen, The Netherlands. Electronic address: lonneke.janssenduijghuijsen…. Hauptthemen laut MEDLINE: Lactose Intolerance, Gastrointestinal Microbiome. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerie van Economische Zaken.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Approximately 70%-100% of the Asian adult population is lactase nonpersistent (LNP). The literature shows that many individuals with the LNP-genotype can consume ≤12 g of lactose without experiencing gastrointestinal discomfort. Repetitive consumption of lactose may reduce intolerance symptoms via adaptation of the gut microbiota. OBJECTIVE: This study aimed to assess the effects of daily consumption of incremental lactose doses on microbiota composition and function, and intolerance symptoms. METHODS: Twenty-five healthy adults of Asian origin, carrying the LNP-genotype were included in this 12-wk before and after intervention trial. Participants consumed gradually increasing lactose doses from 3 to 6 g to 12 g twice daily, each daily dose of 6 g, 12 g, or 24 g being provided for 4 consecutive weeks. Participants handed-in repeated stool samples and underwent a 25 g lactose challenge hydrogen breath test (HBT) before and after the 12-wk intervention. Daily gastrointestinal symptoms and total symptom scores (TSSs) during the lactose challenge were recorded. RESULTS: A significant increase from 5.5% ± 7.6% to 10.4% ± 9.6% was observed in Bifidobacterium relative abundance after the intervention (P = 0.009), accompanied by a 2-fold increase (570 ± 269 U/g; P < 0.001) in fecal β-galactosidase activity compared with baseline (272 ± 158 U/g). A 1.5-fold decrease (incremental area under the curve; P = 0.01) in expired hydrogen was observed during the second HBT (38 ± 35 ppm·min), compared with the baseline HBT (57 ± 38 ppm·min). There was a nonsignificant decrease in TSS (10.6 ± 8.3 before compared with 8.1 ± 7.2 after intervention; P = 0.09). Daily consumption of lactose was well tolerated, with mild to no gastrointestinal complaints reported during the intervention. CONCLUSIONS: Increased levels of Bifidobacterium indicate an adaptation of the gut microbiota upon repetitive consumption of incremental doses of lactose, which was well tolerated as demonstrated by reduced expired hydrogen concentrations during the second 25-g lactose HBT. Bifidobacteria metabolize lactose without gas production thereby potentially reducing intestinal gas formation in the gut of individuals with the LNP-genotype. This increased lactose tolerance possibly lifts the necessity to remove nutrient-rich dairy foods completely from the diet. The trial is registered at the International Clinical Trials Registry Platform: NL9516. The effect of dietary lactose in lactase nonpersistent individuals on gut microbiota.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lactose IntoleranceGastrointestinal MicrobiomeAdultHumansLactaseLactosebeta-GalactosidaseGenotypeHydrogenDietary SupplementsBreath Tests

Stichwörter der Autor:innen

bifidobacteriaclinical trialfecal β-galactosidase activitygut microbial adaptationhydrogen breath testlactase nonpersistencelactose intolerancemicrobiota

Substanzen

LactaseLactosebeta-GalactosidaseHydrogen

Autor:innen und Institutionen

  • Wageningen Food and Biobased Research, Wageningen University & Research, Wageningen, The Netherlands. Electronic address: lonneke.janssenduijghuijsen@wur.nl.
  • FrieslandCampina, Amersfoort, The Netherlands.
  • Wageningen Food and Biobased Research, Wageningen University & Research, Wageningen, The Netherlands.
  • Biomax Labvantage, Planegg, Germany.

Förderung

  • Ministerie van Economische Zaken

Zitieren

APA

JanssenDuijghuijsen, L., Looijesteijn, E., van den Belt, M., Gerhard, B., Ziegler, M., Ariens, R., Tjoelker, R., & Geurts, J. (2024). Changes in gut microbiota and lactose intolerance symptoms before and after daily lactose supplementation in individuals with the lactase nonpersistent genotype. The American Journal of Clinical Nutrition, 119(3), 702-710. https://doi.org/10.1016/j.ajcnut.2023.12.016

Vancouver

JanssenDuijghuijsen L, Looijesteijn E, van den Belt M, Gerhard B, Ziegler M, Ariens R, et al. Changes in gut microbiota and lactose intolerance symptoms before and after daily lactose supplementation in individuals with the lactase nonpersistent genotype. The American Journal of Clinical Nutrition. 2024;119(3):702-710. doi:10.1016/j.ajcnut.2023.12.016

BibTeX
@article{JanssenDuijghuijsen2024,
  author = {JanssenDuijghuijsen, Lonneke and Looijesteijn, Ellen and van den Belt, Maartje and Gerhard, Beatrix and Ziegler, Martin and Ariens, Renata and Tjoelker, Reina and Geurts, Jan},
  title = {Changes in gut microbiota and lactose intolerance symptoms before and after daily lactose supplementation in individuals with the lactase nonpersistent genotype},
  journal = {The American Journal of Clinical Nutrition},
  year = {2024},
  volume = {119},
  number = {3},
  pages = {702--710},
  doi = {10.1016/j.ajcnut.2023.12.016}
}
Kostenlos starten →